Literature DB >> 15209628

Reduced expression of peroxisome proliferator-activated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease.

Jong Eun Yeon1, Kyung Mook Choi, Sei Hyun Baik, Kyoung Oh Kim, Hyoung Joon Lim, Ki Ho Park, Jin Yong Kim, Jong-Jae Park, Jae Seon Kim, Young-Tae Bak, Kwan Soo Byun, Chang Hong Lee.   

Abstract

BACKGROUND: Although the pathogenesis of non-alcoholic fatty liver disease (NAFLD) remains poorly understood, metabolic syndrome associated with insulin resistance is the most reproducible factor in the development of NAFLD. Fat accumulation in hepatocytes results from an imbalance in the input, output and oxidation of fatty acid. Peroxisomes contain a battery of fatty acid oxidizing enzymes, the first of which, acyl-CoA oxidase (AOX), initiates the beta-oxidation spiral. One of the mammalian peroxisome proliferator-activated receptors (PPAR), PPAR-alpha, regulates the transcriptional expression of the enzymes involved in fatty acid beta-oxidation. The aim of the present study was to define the role of PPAR-alpha and AOX in the development of NAFLD using the Otsuka Long-Evans Tokushima fatty (OLETF) rat model.
METHODS: Liver tissue from OLETF (n = 12) and control (n = 10) rats 12, 28, and 40 weeks old were processed for histopathological and western blot analysis. The messenger RNA of PPAR-alpha and AOX were quantified by real-time RT-PCR.
RESULTS: At 40 weeks old, the histological analysis of the OLETF rat liver had steatosis (approximately 66%) and mild inflammation, which were comparable to those in NAFLD. Histological changes were unremarkable in 12 week and 28 week rats. In 12 week OLETF rats, the mRNA of AOX was 63% of the control. Expression of PPAR-alpha mRNA was also reduced to 3% that of the control. Along with the changes of mRNA, the protein expression of PPAR-alpha was also significantly reduced to 17% that of the control. In 28 week and 40 week animals, PPAR-alpha protein expression gradually increased to 75% and 78% that of the control. Expression of PPAR-alpha mRNA was also increased by up to 26% and 110% of the control. AOX, regulated by PPAR-alpha, also increased to 149% and 120% of the control.
CONCLUSION: Reduced expression of PPAR-alpha and AOX was observed even before definite steatosis had developed. The alteration of peroxisomal fatty acid metabolism may have an important role in the development of NAFLD. Copyright 2004 Blackwell Publishing Asia Pty Ltd

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15209628     DOI: 10.1111/j.1440-1746.2004.03349.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  23 in total

1.  Current and novel therapies for the treatment of nonalcoholic steatohepatitis.

Authors:  David van der Poorten; Jacob George
Journal:  Hepatol Int       Date:  2007-07-26       Impact factor: 6.047

2.  Experimental models of non-alcoholic fatty liver disease in rats.

Authors:  Otto Kucera; Zuzana Cervinkova
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

3.  A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury.

Authors:  Gianluca Svegliati-Baroni; Cinzia Candelaresi; Stefania Saccomanno; Gianna Ferretti; Tiziana Bachetti; Marco Marzioni; Samuele De Minicis; Liliana Nobili; Renata Salzano; Alessia Omenetti; Deborah Pacetti; Soeren Sigmund; Antonio Benedetti; Alessandro Casini
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

Review 4.  Developmental programming of pediatric nonalcoholic fatty liver disease: redefining the"first hit".

Authors:  Michael S Stewart; Margaret J R Heerwagen; Jacob E Friedman
Journal:  Clin Obstet Gynecol       Date:  2013-09       Impact factor: 2.190

Review 5.  Non alcoholic fatty liver disease: a clinical approach and review.

Authors:  Maitreyi Raman; Johanne Allard
Journal:  Can J Gastroenterol       Date:  2006-05       Impact factor: 3.522

6.  Elevated sensitivity of macrosteatotic hepatocytes to hypoxia/reoxygenation stress is reversed by a novel defatting protocol.

Authors:  Nir I Nativ; Gabriel Yarmush; Ashley So; Jeffery Barminko; Timothy J Maguire; Rene Schloss; Francois Berthiaume; Martin L Yarmush
Journal:  Liver Transpl       Date:  2014-07-02       Impact factor: 5.799

7.  Insulin resistance in insulin-resistant and diabetic hamsters (Mesocricetus auratus) is associated with abnormal hepatic expression of genes involved in lipid and glucose metabolism.

Authors:  Guosheng Li; Xuhan Liu; Hua Zhu; Lan Huang; Yali Liu; Chunmei Ma; Chuan Qin
Journal:  Comp Med       Date:  2009-10       Impact factor: 0.982

Review 8.  Developmental origins of nonalcoholic fatty liver disease.

Authors:  David E Brumbaugh; Jacob E Friedman
Journal:  Pediatr Res       Date:  2013-11-05       Impact factor: 3.756

9.  Cessation of daily exercise dramatically alters precursors of hepatic steatosis in Otsuka Long-Evans Tokushima Fatty (OLETF) rats.

Authors:  R Scott Rector; John P Thyfault; Matthew J Laye; R Tyler Morris; Sarah J Borengasser; Grace M Uptergrove; Manu V Chakravarthy; Frank W Booth; Jamal A Ibdah
Journal:  J Physiol       Date:  2008-07-10       Impact factor: 5.182

10.  Fenofibrate simultaneously induces hepatic fatty acid oxidation, synthesis, and elongation in mice.

Authors:  Maaike H Oosterveer; Aldo Grefhorst; Theo H van Dijk; Rick Havinga; Bart Staels; Folkert Kuipers; Albert K Groen; Dirk-Jan Reijngoud
Journal:  J Biol Chem       Date:  2009-10-02       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.